# MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

> **NCT04761900** · — · COMPLETED · sponsor: **Ningbo No. 1 Hospital** · enrollment: 3372 (actual)

## Conditions studied

- Metabolic Associated Fatty Liver Disease

## Interventions

- **DIAGNOSTIC_TEST:** the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

## Key facts

- **NCT ID:** NCT04761900
- **Lead sponsor:** Ningbo No. 1 Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 3372 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04761900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04761900, "MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04761900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*